ESR1 and breast carcinoma: Here, we assessed the viability of cells grown in 2D monolayer culture in response to 48 h of treatment with the SERM 4-OHT, an active metabolite of tamoxifen that inhibits estrogen signaling and is a standard-of-care treatment for ER+ breast cancers.